Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?
Zydus Research Center, Ahmedabad, Gujarat, India. nuggehally.srinivas@zyduscadila.com.
N R
NR
Srinivas
D000068879:Adalimumab; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease; D005765:Gastrointestinal Agents; D006801:Humans; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D000069285:Infliximab; D000068879:Adalimumab